Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 5/20 | 0.60 |
| ▸ | TYMP | P19971 | 2/20 | 0.52 |
| ▸ | TYMS | P04818 | 5/20 | 0.49 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.42 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.41 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL912656 | 1.00 | DUT (0.60) | DUTTYMPTYMSP2RY14P2RY2 | |
| SCHEMBL14403996 | 1.00 | DUT (0.60) | DUTTYMPTYMSP2RY14P2RY2 | |
| SCHEMBL19841219 | 1.00 | DUT (0.60) | DUTTYMPTYMSP2RY14P2RY2 | |
| SCHEMBL13444851 | 1.00 | DUT (0.60) | DUTTYMPTYMSP2RY14P2RY2 | |
| SCHEMBL13463839 | 1.00 | DUT (0.60) | DUTTYMPTYMSP2RY14P2RY2 | |
| SCHEMBL4422700 | 0.93 | DUT (0.68) | DUTTYMPTYMSP2RY2P2RY4 | |
| SCHEMBL3492644 | 0.93 | DUT (0.68) | DUTTYMPTYMSP2RY2P2RY4 | |
| SCHEMBL3576747 | 0.93 | DUT (0.68) | DUTTYMPTYMSP2RY2P2RY4 | |
| SCHEMBL10446526 | 0.93 | DUT (0.68) | DUTTYMPTYMSP2RY2P2RY4 | |
| SCHEMBL10446525 | 0.93 | DUT (0.68) | DUTTYMPTYMSP2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12054768-B2 | Methods for detecting agglutination and compositions for use in practicing the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-08-06 | — | — | US | disclosed |
| EP-4123031-A1 | METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS FOR USE IN PRACTICING THE SAME | The Regents of The University of California (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-3283638-B1 | METHODS FOR DETECTING AGGLUTINATION AND USE OF KITS IN PRACTICING THE SAME | UNIV CALIFORNIA (US) | 2022-06-08 | — | — | EP | disclosed |
| US-20210403978-A1 | METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS FOR USE IN PRACTICING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-30 | — | — | US | disclosed |
| US-11149296-B2 | Methods for detecting agglutination and compositions for use in practicing the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-10-19 | — | — | US | disclosed |
| US-20200232005-A1 | Methods of Producing and Using Single-Stranded Deoxyribonucleic Acids and Compositions for Use in Practicing the Same | TAKARA BIO USA, INC. | 2020-07-23 | — | — | US | disclosed |
| US-10584363-B2 | Methods of producing and using single-stranded deoxyribonucleic acids and compositions for use in practicing the same | TAKARA BIO USA, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| US-20180100181-A1 | METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS FOR USE IN PRACTICING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-04-12 | — | — | US | disclosed |
| US-20170349927-A1 | METHODS OF PRODUCING AND USING SINGLE-STRANDED DEOXYRIBONUCLEIC ACIDS AND COMPOSITIONS FOR USE IN PRACTICING THE SAME | TAKARA BIO USA, INC. | 2017-12-07 | — | — | US | disclosed |
| US-8017620-B2 | Dutpase inhibitors | MEDIVIR AB (SE) | 2011-09-13 | — | — | US | disclosed |
| EP-1308452-B1 | Oligonucleotide labeling reactants based on acyclonucleosides and conjugates derived thereof | WALLAC OY (FI) | 2008-03-19 | — | — | EP | disclosed |
| US-7282581-B2 | Oligonucleotide labeling reactants based on acyclonucleosides and conjugates derived thereof | WALLAC OY (FI) | 2007-10-16 | — | — | US | disclosed |
| EP-1701727-A1 | DUTPASE INHIBITORS | Medivir Aktiebolag (SE) | 2006-09-20 | — | — | EP | disclosed |
| US-6949639-B1 | Oligonucleotide labeling reactants and their use | WALLAC OY (FI) | 2005-09-27 | — | — | US | disclosed |
| WO-2005085861-A2 | NUCLEIC ACIDS AND ENCODED POLYPEPTIDES FOR USE IN LIVER DISORDERS AND EPITHELIAL CANCER | ORIDIS BIOMED FORSCHUNGS- UND ENTWICKLUNGS GMBH (AT) | 2005-09-15 | — | — | WO | disclosed |
| WO-2005065689-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2005-07-21 | — | — | WO | disclosed |
| US-20040260080-A1 | Oligonucleotide labeling reactants and their use | HOVINEN JARI (FI) | 2004-12-23 | — | — | US | disclosed |
| US-20030118999-A1 | Oligonucleotide labeling reactants based on acyclonucleosides and conjugates derived thereof | WALLAC OY (FI) | 2003-06-26 | — | — | US | disclosed |
| EP-1308452-A2 | Oligonucleotide labeling reactants based on acyclonucleosides and conjugates derived thereof | WALLAC OY (FI) | 2003-05-07 | — | — | EP | disclosed |
| EP-1152010-A2 | Oligonucleotide labeling reactants and their use | WALLAC OY (FI) | 2001-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040260080-A1 | Oligonucleotide labeling reactants and their use | SSU72, LIG4, NSUN2 | DUT 15/4885TYMP 1443/4885TYMS 867/4885 |
| US-20030118999-A1 | Oligonucleotide labeling reactants based on acyclonucleosides and conjugates derived thereof | PCNA, DUT, POLL | DUT 2/4885TYMP 79/4885TYMS 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.